- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Positive results reported for AMD treatment
Plymouth Meeting, PA—Six patients treated with 40 mg of Genaera Corp.'s squalamine lactate (Evizon) had preserved or improved vision in both eyes suffering from wet age-related macular degeneration through a 4-month study, according to the company, which released preliminary results of a phase II clinical trial.
Plymouth Meeting, PA-Six patients treated with 40 mg of Genaera Corp.'s squalamine lactate (Evizon) had preserved or improved vision in both eyes suffering from wet age-related macular degeneration through a 4-month study, according to the company, which released preliminary results of a phase II clinical trial.
The multicenter, open-label trial also showed that six patients treated with 10 mg of the anti-angiogenic drug demonstrated 90% of eyes had preserved or improved vision 4 months after initiating therapy.
Among patients receiving the 40-mg dose, the greatest degree of improvement at 4 months was a gain of 18 letters on the ETDRS chart, while the greatest degree of loss was 12 letters.
